Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) announced its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14), Briefing.com reports. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the company earned ($1.17) earnings per share. The business’s revenue was up 78.3% on a year-over-year basis.

Apellis Pharmaceuticals Trading Up 1.1 %

APLS traded up $0.32 during mid-day trading on Wednesday, hitting $28.40. The stock had a trading volume of 1,796,003 shares, compared to its average volume of 1,771,285. The stock’s fifty day simple moving average is $31.58 and its 200-day simple moving average is $37.26. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -10.28 and a beta of 0.87. Apellis Pharmaceuticals has a 1-year low of $24.34 and a 1-year high of $73.80.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

APLS has been the subject of several analyst reports. HC Wainwright cut their price target on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday. JPMorgan Chase & Co. cut their price target on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Wells Fargo & Company decreased their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday. Scotiabank reduced their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Finally, William Blair began coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They issued an “outperform” rating for the company. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.24.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).